AIMS/HYPOTHESIS: Individuals with type 1 diabetes have an increased incidence of coronary artery disease (CAD) and a higher risk of cardiovascular death compared with individuals of the same age in the general population. While chronic hyperglycaemia and insulin resistance partially explain excess CAD, little is known about the potential genetic determinants of accelerated coronary atherosclerosis in type 1 diabetes. The aim of the present study was to evaluate the association of apolipoprotein A-IV (APOA4) polymorphisms with coronary artery calcification (CAC) progression, a marker of subclinical atherosclerosis. SUBJECTS AND METHODS: Two previously well-studied functional APOA4 polymorphisms resulting in the substitution of the amino acid Thr for Ser at codon 347 and Gln for His at codon 360 were genotyped in 634 subjects with type 1 diabetes and 739 non-diabetic control subjects, the participants of the prospective Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. RESULTS: The His360 allele was associated with a significantly higher risk of CAC progression among patients with type 1 diabetes (33.7 vs 21.2%, p=0.014), but not in the control subjects (14.1 vs 11.1%, p=0.42). Logistic regression analysis confirmed that the presence of the APOA4 His360 allele predicts an increased risk of progression of coronary atherosclerosis in adults with type 1 diabetes of long duration (odds ratio = 3.3, p=0.003 after adjustment for covariates associated with CAD risk). CONCLUSIONS / INTERPRETATION: This is the first report suggesting an association between the APOA4 Gln360His polymorphism and risk of CAC progression in subjects with type 1 diabetes. Additional studies are needed to explore potential interactions between APOA4 genotypes and metabolic/oxidative stress components of the diabetic milieu leading to rapid progression of atherosclerosis.
AIMS/HYPOTHESIS: Individuals with type 1 diabetes have an increased incidence of coronary artery disease (CAD) and a higher risk of cardiovascular death compared with individuals of the same age in the general population. While chronic hyperglycaemia and insulin resistance partially explain excess CAD, little is known about the potential genetic determinants of accelerated coronary atherosclerosis in type 1 diabetes. The aim of the present study was to evaluate the association of apolipoprotein A-IV (APOA4) polymorphisms with coronary artery calcification (CAC) progression, a marker of subclinical atherosclerosis. SUBJECTS AND METHODS: Two previously well-studied functional APOA4 polymorphisms resulting in the substitution of the amino acid Thr for Ser at codon 347 and Gln for His at codon 360 were genotyped in 634 subjects with type 1 diabetes and 739 non-diabetic control subjects, the participants of the prospective Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. RESULTS: The His360 allele was associated with a significantly higher risk of CAC progression among patients with type 1 diabetes (33.7 vs 21.2%, p=0.014), but not in the control subjects (14.1 vs 11.1%, p=0.42). Logistic regression analysis confirmed that the presence of the APOA4His360 allele predicts an increased risk of progression of coronary atherosclerosis in adults with type 1 diabetes of long duration (odds ratio = 3.3, p=0.003 after adjustment for covariates associated with CAD risk). CONCLUSIONS / INTERPRETATION: This is the first report suggesting an association between the APOA4 Gln360His polymorphism and risk of CAC progression in subjects with type 1 diabetes. Additional studies are needed to explore potential interactions between APOA4 genotypes and metabolic/oxidative stress components of the diabetic milieu leading to rapid progression of atherosclerosis.
Authors: Wenchun Qu; Thuy T Le; Stanley P Azen; Min Xiang; Nathan D Wong; Terence M Doherty; Robert C Detrano Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112
Authors: Kim Pettersson-Fernholm; Carol Forsblom; Barry I Hudson; Markus Perola; Peter J Grant; Per-Henrik Groop Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Janet K Snell-Bergeon; John E Hokanson; Lisa Jensen; Todd MacKenzie; Gregory Kinney; Dana Dabelea; Robert H Eckel; James Ehrlich; Satish Garg; Marian Rewers Journal: Diabetes Care Date: 2003-10 Impact factor: 19.112
Authors: L Tarnow; F Cambien; P Rossing; F S Nielsen; B V Hansen; L Lecerf; O Poirier; S Danilov; S Boelskifte; K Borch-Johnsen Journal: Diabetologia Date: 1995-07 Impact factor: 10.122
Authors: S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson Journal: Diabetologia Date: 2003-05-28 Impact factor: 10.122
Authors: Xiaohong Ruby Xu; Yiming Wang; Reheman Adili; Lining Ju; Christopher M Spring; Joseph Wuxun Jin; Hong Yang; Miguel A D Neves; Pingguo Chen; Yan Yang; Xi Lei; Yunfeng Chen; Reid C Gallant; Miao Xu; Hailong Zhang; Jina Song; Peifeng Ke; Dan Zhang; Naadiya Carrim; Si-Yang Yu; Guangheng Zhu; Yi-Min She; Terry Cyr; Wenbin Fu; Guoqing Liu; Philip W Connelly; Margaret L Rand; Khosrow Adeli; John Freedman; Jeffrey E Lee; Patrick Tso; Patrizia Marchese; W Sean Davidson; Shaun P Jackson; Cheng Zhu; Zaverio M Ruggeri; Heyu Ni Journal: Nat Commun Date: 2018-09-06 Impact factor: 14.919